ArticleThe oncologist2020

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.

Aditya Bardia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.